Phase 3 N=246 Randomized Triple-blind Treatment

Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear

Ametropia

Bottom Line

View on ClinicalTrials.gov: NCT00691197 ↗

Enrolled (actual)

246

Serious AEs

0.0%

Results posted

Dec 2009

Primary outcome: Primary: Best Corrected Visual Acuity — 0.65; 1.33; 98.06; 98.67 Percentage of Participants

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: Carboxymethylcellulose sodium and Glycerin (Device); Carboxymethylcellulose sodium (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Allergan
Primary completion: Oct 2008

Outcome Measures

Outcome	Result	p-value
PRIMARY Best Corrected Visual Acuity	0.65; 1.33; 98.06; 98.67; 1.29; 0	—
SECONDARY Corneal Staining	0; 1	—

Summary

Testing the Safety and Acceptability of Using a Rewetting Drop with Contact Lenses

Eligibility Criteria

Inclusion Criteria

Adapted contact lens wearer

Exclusion Criteria

Monovision lens wearer, ocular or systemic disease, pregnant or planning to become pregnant

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00691197). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.